HAVCR2 and neoplasm: Though this possibility has yet to be investigated experimentally, it is clear that there are diverse immune regulatory effects mediated by TIM‐3 in tumor‐associated DC, and these pathways, as well as factors that drive TIM‐3 expression by DC, offer multiple points for therapeutic intervention to relieve suppression of these cells within the TME.